GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 1.29 trillion. The enterprise value is 1.31 trillion.

Market Cap	1.29T
Enterprise Value	1.31T

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 39.68 million shares outstanding. The number of shares has increased by 0.79% in one year.

Current Share Class	n/a
Shares Outstanding	39.68M
Shares Change (YoY)	+0.79%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	1.59%
Owned by Institutions (%)	6.41%
Float	29.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.48
PB Ratio	17.20
P/TBV Ratio	18.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-24.65
EV / Sales	20.96
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-53.69

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.61.

Current Ratio	1.16
Quick Ratio	0.83
Debt / Equity	0.61
Debt / EBITDA	n/a
Debt / FCF	-1.86
Interest Coverage	-18.60

Financial Efficiency

Return on equity (ROE) is -54.19% and return on invested capital (ROIC) is -19.77%.

Return on Equity (ROE)	-54.19%
Return on Assets (ROA)	-17.52%
Return on Invested Capital (ROIC)	-19.77%
Return on Capital Employed (ROCE)	-34.61%
Revenue Per Employee	337.27M
Profits Per Employee	-286.71M
Employee Count	186
Asset Turnover	0.45
Inventory Turnover	4.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +63.08% in the last 52 weeks. The beta is 0.77, so GemVax&KAEL's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	+63.08%
50-Day Moving Average	18,657.20
200-Day Moving Average	14,337.55
Relative Strength Index (RSI)	80.68
Average Volume (20 Days)	794,980

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 62.73 billion and -53.33 billion in losses. Loss per share was -1,348.76.

Revenue	62.73B
Gross Profit	18.82B
Operating Income	-38.95B
Pretax Income	-53.49B
Net Income	-53.33B
EBITDA	-34.61B
EBIT	-38.95B
Loss Per Share	-1,348.76

Full Income Statement

Balance Sheet

The company has 20.52 billion in cash and 45.56 billion in debt, giving a net cash position of -25.04 billion or -631.05 per share.

Cash & Cash Equivalents	20.52B
Total Debt	45.56B
Net Cash	-25.04B
Net Cash Per Share	-631.05
Equity (Book Value)	74.96B
Book Value Per Share	1,889.16
Working Capital	5.20B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -21.57 billion and capital expenditures -2.91 billion, giving a free cash flow of -24.48 billion.

Operating Cash Flow	-21.57B
Capital Expenditures	-2.91B
Free Cash Flow	-24.48B
FCF Per Share	-617.03

Full Cash Flow Statement

Margins

Gross margin is 30.00%, with operating and profit margins of -62.09% and -85.01%.

Gross Margin	30.00%
Operating Margin	-62.09%
Pretax Margin	-85.26%
Profit Margin	-85.01%
EBITDA Margin	-55.18%
EBIT Margin	-62.09%
FCF Margin	n/a

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.79%
Shareholder Yield	-0.79%
Earnings Yield	-4.14%
FCF Yield	-1.90%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 2.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.43
Piotroski F-Score	n/a